Apellis Pharmaceuticals Inc (NAS:APLS)
$ 40.07 -0.26 (-0.64%) Market Cap: 4.86 Bil Enterprise Value: 4.65 Bil PE Ratio: 0 PB Ratio: 18.22 GF Score: 38/100

Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 04:20PM GMT
Release Date Price: $41.17 (+5.92%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

Alright. Thanks, everyone, for joining us this morning at the Goldman Sachs Global Healthcare Conference. We could not be more pleased to have the team from Apellis Pharmaceuticals with us today. Telling us about the story, I mean, pretty slow, nothing's really going on for you guys these days, right, just filling out. Kidding, obviously, this is really -- this is like the important time for the company. So we're really excited you guys join us today.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you, Madhu.

Questions & Answers

Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

Awesome. So let's start with a discussion of your kind of major C3 drug pegcetacoplan, I'm going to call it PEG for short, in geographic atrophy, also known as GA. So start by kind of walking through at a kind of high level, the mechanistic rationale for targeting

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot